Aktie A2QCWY FUSEN PHARMACEUTICAL COMPANY LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Fusen Pharmaceutical Company Limited

Aktien

A2QCWY

KYG370981030

1652

Verzögert Hong Kong S.E.
Andere Börsenplätze
 04:18:02 23.05.2024 		% 5 Tage % 1. Jan.
1,18 HKD +2,61 % Intraday Chart für Fusen Pharmaceutical Company Limited +12,38 % -13,87 %
04.04. Antrag von Fusen Pharmaceutical zur Behandlung von Typ-2-Diabetes von chinesischer Aufsichtsbehörde angenommen MT
03.04. Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited gibt bekannt, dass die National Medical Products Administration der Volksrepublik China den Antrag auf Markteinführung von Metformin Empagliflozin Tabletten (I) angenommen hat CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)
Fusen Pharmaceutical Posts Higher Loss in 2023
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Fusen Pharmaceutical Forecasts Return to Profitability in H1
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022
Fusen Pharmaceutical to Swing to Loss in 2022
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches
Fusen Pharmaceutical Company Limited Announces Change of Principal Place of Business in Hong Kong
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QCWY Aktie
  4. Nachrichten Fusen Pharmaceutical Company Limited
  5. Andere Sprachen
equities